期刊文献+

汉族人群中血管紧张素转换酶抑制剂所致咳嗽与血管紧张素转换酶基因及缓激肽β2受体基因多态性的关系 被引量:3

The Association between ACE Inhibitor(ACEI)-Induced Cough and the Polymorphism of Angiotensin Converting Enzyme(ACE) Gene and Bradykinin β2 Receptor(BDKRB2) Gene in Han Nationality
原文传递
导出
摘要 目的:探讨汉族人群中血管紧张素转换酶抑制剂(ACEI)所致咳嗽与血管紧张素转换酶(ACE)基因及缓激肽β2受体(BDK-RB2)基因多态性的关系。方法:应用聚合酶链反应(PCR)方法,检测汉族人群中151例由于服用ACEI引起的咳嗽患者及151例未发生咳嗽的患者的ACE I/D及BDKRB2 C/T的多态性,并采用紫外法检测ACE活性。结果:发现ACE基因分布在咳嗽组中II型为47.0%,ID型为42.4%,DD型为10.6%;无咳嗽组分别为39.7%、47.0%、13.3%,两组相比其差异具有统计学意义(P<0.01);BDKRB2基因分布在咳嗽组中CC型为21.3%,CT型为50.0%,TT型为28.7%,无咳嗽组分别为22.5%、47.7%、29.8%,两组相比其差异无统计学意义(P>0.05);咳嗽组ACE活性水平为([28.3±10.1)U/L]明显低于无咳嗽组([40.2±9.4)U/L],两组相比其差异具有统计学意义(P<0.01)。结论:汉族人群中ACEI所致咳嗽与ACE基因多态性及血清ACE水平有关,BDKRB2 C/T与咳嗽间未发现有统计学意义的关联。 Objective: To investigate the association between angiotensin converting enzyme inhibitor (ACEI)-induced cough and the polymorphism of angiotensin converting enzyme (ACE) gene and bradykinin 62 receptor (BDKRB2) gene in Hart nationality. Methods: Polymerase chain reaction (PCR) was used to examine ACE I/D and BDKRB2 CT polymorphism in 151 ACEI-induced cough subjects and 151 no cough subjects in Han population. And UV-method was used to detect the ACE activity. Results:ACE gene distribution in the cough group: type II was 47.0%, ID genotype was 42.4%, DD genotype was 10.6%; Non-cough group were 39.7%, 47.0%, 13.3% respectively, and there was statistically significant difference between the two groups(P〈0.01); BDKRB2 Gene distribution in the cough group: the CC genotype was 21.3%, CT genotype was 50.0%, TT genotype was 28.7%, non-cough group were 22.5%, 47.7%, 29.8% respectively, and there was not statistically significant between the two groups ( P〉 0.05); The level of ACE activity in the Cough group [(28.3 ± 10.1) U / L,] was significantly lower than non-cough group [(40.2 ± 9.4) U / L,(P 〈0.01).]. Conclusions: For ban population, ACEI-induced cough related to ACE gene polymorphism and serum ACE activity, and there was no statistically significant association between BDKRB2 C / T and cough.
出处 《现代生物医学进展》 CAS 2012年第31期6011-6014,共4页 Progress in Modern Biomedicine
基金 湖南省科技厅重点项目资助(S2009S2032)
关键词 血管紧张素转换酶抑制剂 咳嗽 血管紧张素转换酶基因 缓激肽β2受体基因 Angiotensin converting enzyme inhibitor Cough Angiotensin converting enzyme gene Bradykinin β2 receptor gene
  • 相关文献

参考文献21

二级参考文献44

  • 1叶阮健,何权瀛,改军,尚颖.高血压患者服用血管紧张素转换酶抑制剂后咳嗽机制的前瞻性研究[J].中华结核和呼吸杂志,2004,27(9):581-584. 被引量:18
  • 2王建国.色甘酸钠治疗血管紧张素转换酶抑制剂引起的咳嗽[J].国外医学:药学分册,1995,23:53-53.
  • 3[1]Dicpinigaitis PV.Angiotensin-converting enzyme inhibitor-induced cough:ACCP evidence-based clinical practice guidelines[J].Chest,2006,129(1 Suppl):169S-173S.
  • 4[4]Mooraki A,Jenabi A,Jabbari M,et al.Noscapine suppresses angiotensin converting enzyme inhibitors-induced cough[J].Nephrology,2005,10:348-350.
  • 5Umemura K, Nakashima M, Saruta T. Thromboxane A2 synthetase inhibition suppresses cough induced by angiotensin converting enzyme inhibitors. Life Science, 1997,60:1583-1588.
  • 6Ding PYA, Hu OYP, Pool PE, et al. Does Chinese ethnicity affect the pharmacokinetics and pharmacodynamics of angiotensinconverting enzyme inhibitors? J Hum Hypertens, 2000, 14 : 163-170.
  • 7Karch F, Lasagna L. Adverse drug reactions: a critical review.JAMA, 1975, 234: 1236-1241.
  • 8Furuya K, Yamaguchi E, Hirabayashi T, et al. Angiotensin- I -converting enzyme gene polymorphism and susceptibility to cough.Lancet, 1994,343:354.
  • 9Takahashi T, Yamaguchi E, Furuya K, et al. The ACE gene polymorphism and cough threshold for capsaicin after cilazapril usage. Respir Med, 2001,95 : 130-135.
  • 10Zee RY, Rao VS, Paster RZ, et al. Three candidate genes and angiotensin-converting enzyme inhibitor-related cough, a pharmacogenetic analysis. Hypertension, 1998, 31:925-928.

共引文献31

同被引文献57

  • 1叶阮健,何权瀛,改军,尚颖.高血压患者服用血管紧张素转换酶抑制剂后咳嗽机制的前瞻性研究[J].中华结核和呼吸杂志,2004,27(9):581-584. 被引量:18
  • 2无.血管紧张素转换酶抑制剂在心血管病中应用中国专家共识[J].中华心血管病杂志,2007,35(2):97-106. 被引量:135
  • 3Mahmoudpour SH, Leusink M, der Putten LV, et al. Pharmacogenetics of ACE inhibitor-induced angioedema and cough a systematic review and meta-analysis. Pharmacogenomics, 2013 14 : 249 -260.
  • 4Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest, 2006,129 : 169-173.
  • 5Adigun AQ, Ajayi AA. Angiotensin converting enzyme inhibitor induced cough in Nigerians. West Afr J Med,2001,20 :46-47.
  • 6Wyskida K,Jura-Szoltys E, Smertka M, et al. Factors that favor the occurrence of cough in patients treated with ramipfil--a pharmacoepidemiological study. Med Sci Monit,2012,18 : 21-28.
  • 7Tseng DS, Kwong J, Rezvani F, et al. Angiotensin-converting enzyme-related cough among Chinese-Americans. Am J Med,2010, 123 : 11-15.
  • 8Baker-Smith CM, Benjamin DK Jr, Califf RM, et al. Cough in pediatric patients receiving angiotensin-converting enzyme inhibitor therapy or angiotensin receptor blocker therapy in randomized controlled trials. Clin Pharmacol Ther,2010,87:668-671.
  • 9Tumanan-Mendoza BA, Dans AL, Villacin LL, et al. Dechallenge and rechallenge method showed different incidences of cough among four ACE-Is. J Clin Epidemiol,2007,60:547-553.
  • 10Boonyapisit W, Tresukosol D. Comparison of the incidence of imidapril and enalapril induced cough. J Med Assoc Thai,2010,93 Suppl 1 :S48-S53.

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部